Perspective Of Breast Cancer Proliferation Through Lfa-1 Mrna and Icam-1 Mrna Expression with Lfa-1 Or Lfa-1 Agonists On Ki-67 Examination Indicators: A Brief Review

Research on immunity of breast cancer, particularly the role of T lymphocyte infiltration and regulatory T cells measured through peripheral blood. This review aims to identify new indicators that can predict prognosis and discover the way for more effective immunotherapy in breast cancer. The immune system responds through various defense mechanisms, including the cytotoxic response of T cells. T cells can recognize specific tumor antigens on the surface of cancer cells through T cell receptors, which then trigger the process of destroying the target cells. LFA-1 (Lymphocyte Function-associated Antigen 1) plays a crucial role as an initiator of immunological interaction between cytotoxic T (Natural Killer) cells and cancer cells. This interaction is essential for the effectiveness of the immune response against cancer. ICAM-1 (Intercellular Adhesion Molecule 1) is involved in the metastasis of breast cancer through complex mechanisms. In the process of breast cancer metastasis, ICAM-1 may function to promote the migration and invasion of cancer cells into other tissues. This paper summarizes research on the role of LFA-1 and ICAM-1 in breast cancer proliferation treated with LFA-1 antagonists and agonists. The roles of LFA-1 and ICAM-1 in breast cancer are critical to further exploring the involvement of these molecules in breast cancer. The relationship between LFA-1 and ICAM-1 mRNA expression with the administration of LFA-1 antagonists and agonists may serve as a reference for discovering treatments aimed at inhibiting the proliferative activity of breast cancer, providing new knowledge in the medical field, particularly in oncology.